GLP-1 diabetes drugs slash dementia risk more than metformin in major study of 174,000 patients
A new study just flipped the script on diabetes treatment. Researchers tracked 174,458 patients with type 2 diabetes and found that GLP-1 receptor agonists cut dementia risk more effectively than metformin. The data spans 20 years. The results aren’t subtle. The study pulled anonymized health records from the Trinetx global network. Each drug cohort had …